PMID- 27184764
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20220316
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 5
IP  - 8
DP  - 2016 Aug
TI  - Fascin-1 as a novel diagnostic marker of triple-negative breast cancer.
PG  - 1983-8
LID - 10.1002/cam4.746 [doi]
AB  - In some cases of breast cancer, diagnosis of triple-negative breast cancer (TNBC) 
      requires further fluorescence in situ hybridization (FISH) for determining human 
      epidermal growth factor receptor 2 (HER2) status. However, few cases undergo FISH 
      in China, leading to difficulty regarding subsequent treatment decisions. Here, 
      we used immunohistochemical analysis to explore expression of fascin-1, an 
      actin-bundling protein, as a diagnostic marker of TNBC. A total of 457 cases of 
      breast cancer were divided into four molecular subtypes, including 82 cases 
      (17.9%) of TNBC, 81 (17.7%) of HER2-enriched, 185 (40.5%) of luminal A, and 109 
      (23.9%) of luminal B. Positive fascin-1 expression was seen in 144 cases (31.5%), 
      including 77 (16.8%) strong positive cases. Rates of positive and strong positive 
      expression of fascin-1 were significantly higher in cases of TNBC than in the 
      other molecular subtypes. In all cases of breast cancer, the sensitivities and 
      specificities of positive and strong positive fascin-1 expression for predicting 
      TNBC were 87.8% and 80.8%, and 78.0% and 96.5%, respectively. In cases of hormone 
      receptor-negative breast cancer, the sensitivities and specificities of positive 
      and strong positive fascin-1 expression for predicting TNBC were 87.8% and 61.7%, 
      and 78.0% and 92.6%, respectively. In 24 cases with estrogen receptor (ER)-, PR-, 
      and HER2 2 +  equivocal status who underwent FISH, the sensitivity and 
      specificity of strong positive fascin-1 expression for predicting TNBC were 71.4% 
      and 90.0%. These results suggest that strong positive fascin-1 expression can be 
      used as a diagnostic marker of TNBC.
CI  - (c) 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Wang, Chao-Qun
AU  - Wang CQ
AD  - Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Tang, Chih-Hsin
AU  - Tang CH
AD  - Graduate Institute of Basic Medical Science, China Medical University, Taichung, 
      Taiwan.
AD  - Department of Pharmacology, School of Medicine, China Medical University, 
      Taichung, Taiwan.
AD  - Department of Biotechnology, College of Health Science, Asia University, 
      Taichung, Taiwan.
FAU - Chang, Hao-Teng
AU  - Chang HT
AD  - Graduate Institute of Basic Medical Science, China Medical University, Taichung, 
      Taiwan.
FAU - Li, Xiao-Ni
AU  - Li XN
AD  - Hefei National Laboratory for Physical Sciences at Microscale and School of Life 
      Sciences, University of Science and Technology of China, Hefei, Anhui, China.
FAU - Zhao, Yong-Ming
AU  - Zhao YM
AD  - Department of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Su, Chen-Ming
AU  - Su CM
AD  - Laboratory of Biomedicine, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Hu, Gui-Nv
AU  - Hu GN
AD  - Department of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Zhang, Tao
AU  - Zhang T
AD  - Department of Control and Prevention of Endemic & Parasitic Diseases, Anhui 
      Provincial Center for Disease Control and Prevention, Hefei, Anhui, China.
FAU - Sun, Xin-Xin
AU  - Sun XX
AD  - Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Zeng, Yue
AU  - Zeng Y
AD  - Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Du, Zhang
AU  - Du Z
AD  - Department of Surgical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Department of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
FAU - Huang, Bi-Fei
AU  - Huang BF
AD  - Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical 
      University, Dongyang, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160517
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Carrier Proteins)
RN  - 0 (FSCN1 protein, human)
RN  - 0 (Microfilament Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Biomarkers, Tumor
MH  - Carrier Proteins/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Microfilament Proteins/genetics/*metabolism
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Sensitivity and Specificity
MH  - Triple Negative Breast Neoplasms/*diagnosis/*metabolism
MH  - Tumor Burden
PMC - PMC4971926
OTO - NOTNLM
OT  - Breast cancer
OT  - fascin-1
OT  - immunohistochemistry
OT  - triple-negative breast cancer
EDAT- 2016/05/18 06:00
MHDA- 2017/11/29 06:00
PMCR- 2016/05/17
CRDT- 2016/05/18 06:00
PHST- 2016/02/24 00:00 [received]
PHST- 2016/02/26 00:00 [revised]
PHST- 2016/04/02 00:00 [accepted]
PHST- 2016/05/18 06:00 [entrez]
PHST- 2016/05/18 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/05/17 00:00 [pmc-release]
AID - CAM4746 [pii]
AID - 10.1002/cam4.746 [doi]
PST - ppublish
SO  - Cancer Med. 2016 Aug;5(8):1983-8. doi: 10.1002/cam4.746. Epub 2016 May 17.